Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Links shared publicly online about this topic.

0
total visits

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Tolero Pharmaceuticals and MannKind Corporation today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases.

View full resource at news-medical.net

Tags: